Loading
A phase 2 trial of Sonesitatug vedotin, Rilvegostomig, Trastuzumab, Trastuzumab deruxtecan, Capecitabine and Fluorouracil (5-FU) in oesophageal cancer, run by AstraZeneca, now recruiting.
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma is a phase 2 interventional study registered as NCT07069712 by AstraZeneca, with 100 participants planned, started 2025-07-17 and due to reach its primary completion in 2027-11-03. Interventions recorded: Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU) and FLOT Chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sonesitatug vedotin, Rilvegostomig, Oesophageal and junctional adenocarcinoma, T-cell exhaustion and CAR-T persistence and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Trastuzumab deruxtecan, Trastuzumab and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Shares Trastuzumab deruxtecan, Trastuzumab, Fluorouracil (5-FU), Capecitabine and the tag pipeline.
Shares Parexel, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/